|
Daily Medical Update
Drug-induced myopathy
Thursday, August 27, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Journal of the American Heart Association (2026) - Randomized Controlled Trial
Key Findings
- Statin-associated muscle symptoms occurred less often with moderate-intensity rosuvastatin plus ezetimibe than with rosuvastatin 20 mg (0.7% vs 5.4%; P=0.021).
- LDL-C target attainment was comparable, while combination therapy produced greater non-HDL-C reduction and less increase in lipoprotein(a).
📋 Practice Implication: For older adults with ASCVD and tolerability concerns, moderate-intensity statin plus ezetimibe is a clinically supported way to preserve LDL-C control while reducing reported muscle symptoms.
|
Medicina (Kaunas, Lithuania) (2026) - Review
Key Findings
- Blinded evidence showed that statins increased muscle pain only slightly, with the excess concentrated mainly during the first year of therapy.
- The review concluded that most muscle symptoms reported during statin treatment are not pharmacologically caused by the statin, although severe toxicity can occur with increased exposure or other risk factors.
📋 Practice Implication: Use structured assessment, selective CK testing, alternative-cause evaluation, and dechallenge/rechallenge or switching before permanently discontinuing statin therapy for presumed SAMS.
|
Journal of nutritional science (2025) - Meta-Analysis/Systematic Review
Key Findings
- Four of seven included trials reported a significant reduction in statin-associated muscle symptoms, while three found no significant change.
- Across 389 patients, CoQ10 reduced pain intensity versus control by a weighted mean difference of -0.96 (95% CI -1.88 to -0.03; P<0.05).
📋 Practice Implication: CoQ10 can be discussed as an adjunct for symptomatic patients, but the modest pooled effect and mixed trial results do not make it a replacement for statin adjustment or alternative lipid-lowering therapy.
|
International journal of cardiology (2026) - Randomized Controlled Trial
Key Findings
- At 30 days, the composite LDL-C target occurred in 63% of the very-high-intensity group and 52% of the high-intensity group, without a significant difference (P=0.13).
- Very-high-intensity therapy achieved LDL-C below 55 mg/dL more often (86% vs 73%), but intolerance-related dose reduction was more frequent (8% vs 2%; P=0.03).
📋 Practice Implication: After AMI, the incremental LDL-C benefit of very-high-intensity dosing should be weighed against its higher intolerance burden when ezetimibe is already included.
|
European journal of clinical pharmacology (2026) - Observational Study
Key Findings
- At least one substance with OATP1B1-inhibiting properties was co-reported with a statin in 54% of suspected SAMS individual case safety reports.
- Antidiabetic and cardiovascular drugs were the most common reported classes among the 54% of cases with an OATP1B1-inhibiting co-medication.
📋 Practice Implication: When SAMS develops, review antidiabetic and cardiovascular co-medications for transporter-mediated interactions before escalating the statin dose or labeling the patient as intrinsically statin-intolerant.
|
|
💡
Summary
Recent evidence supports a lower-dose statin plus ezetimibe strategy in older adults: it achieved comparable LDL-C target attainment with fewer statin-associated muscle symptoms than high-intensity statin monotherapy. A pragmatic acute myocardial infarction trial found little difference in composite LDL-C success between high- and very-high-intensity statins when both included ezetimibe, but more intolerance-related dose reductions with the higher intensity. Across statin-myopathy management, CoQ10 showed a modest pooled pain reduction, while review and pharmacovigilance data underscore separating non-pharmacologic symptoms from true toxicity and checking interacting OATP1B1 inhibitors.
|
|